Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

NCT07453095 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Glofitamab

Sponsor

Fondazione Italiana Linfomi - ETS